Please login to the form below

Not currently logged in
Email:
Password:

Kalydeco

This page shows the latest Kalydeco news and features for those working in and with pharma, biotech and healthcare.

Vertex continues upward trajectory with French Orkambi deal

Vertex continues upward trajectory with French Orkambi deal

The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor).

Latest news

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Luckily, that plan B was waiting in the wings: Kalydeco (ivacaftor), the first ever disease-modifying treatment for cystic fibrosis gained approval in 2012. ... Jeff Leiden, Vertex CEO. The company built on its initial ‘precision medicine’ Kalydeco,

  • The Orkambi row explained The Orkambi row explained

    He says it has overpaid for Kalydeco by £400m over five years – not a ‘fair and reasonable price’. ... December 2016: NHSE approves expanded use of Kalydeco to two-to-five-year-olds in England, benefiting around 50 children.

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products. ... an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... time of Kalydeco’s arrival in 2012.

  • The good, the bad and the ugly The good, the bad and the ugly

    Vertex has two - with Kalydeco sitting alongside Orkambi in an impressive respiratory portfolio.”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics